Wei-Dong Jiang

Title: Wei-Dong Jiang: Innovator in Antibody Development

Introduction

Wei-Dong Jiang is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of biotechnology, particularly in the development of innovative antibodies. His work focuses on enhancing therapeutic options for various diseases through advanced antibody technologies.

Latest Patents

Wei-Dong Jiang holds a patent for "Anti-TIGIT antibodies, multispecific antibodies comprising the same, and methods of using the same." This patent provides anti-TIGIT antibodies that bind to the T cell immunoreceptor with Ig and ITIM domains (TIGIT). The invention includes multispecific anti-TIGIT antibodies with binding specificity for TIGIT and one or more additional antigens. In certain embodiments, the anti-TIGIT antibodies comprise a single domain antibody that binds to TIGIT. Additionally, the one or more additional antigens may include Programmed cell death ligand 1 (PDL1). This innovative approach has the potential to improve cancer immunotherapy.

Career Highlights

Wei-Dong Jiang is associated with Shanghai Henlius Biotech Inc., where he continues to advance his research and development efforts. His expertise in antibody engineering has positioned him as a key player in the biotechnology sector. His contributions are vital in the ongoing quest for effective treatments for various health conditions.

Collaborations

Wei-Dong Jiang collaborates with notable colleagues, including Ming Yang and Wenfeng Xu. Their combined efforts enhance the research capabilities and innovation potential within their organization.

Conclusion

Wei-Dong Jiang's work in the field of antibody development exemplifies the impact of innovative research on healthcare. His patent on anti-TIGIT antibodies represents a significant advancement in therapeutic strategies. Through his career at Shanghai Henlius Biotech Inc., he continues to contribute to the evolution of biotechnology and improve patient outcomes.